Lack of EGFR Mutation Test Results Before Starting First Line Therapy for Advanced Lung Cancer Worsens Outcomes

Lack of EGFR Mutation Test Results Before Starting First Line Therapy for Advanced Lung Cancer Worsens Outcomes

27/04/2015

GENEVA— Almost one in four patients with advanced lung cancer in Europe, Asia and the US are not receiving EGFR test results before being started on treatment—according to a report presented at the Eu

GENEVA— Almost one in four patients with advanced lung cancer in Europe, Asia and the US are not receiving EGFR test results before being started on treatment—according to a report presented at the European Lung Cancer Conference by James Spicer MRCP PhD, a consultant in medical oncology at Guy’s Hospital, King’s College London. He explained his concern to Oncology Times reporter Peter Goodwin that anti-EGFR therapies are not being deployed optimally and that outcomes are negatively impacted.